Keyphrases
Diabetes
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Cardioprotection
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Type II Inhibitor
40%
Sodium-glucose Cotransporter
40%
Disease Treatment
20%
Liver Disease Progression
20%
Oxidative Stress
10%
Potential Impact
10%
Human Studies
10%
Apoptosis
10%
In Vitro Study
10%
Health Problems
10%
Disease Pathogenesis
10%
Lifestyle Modification
10%
Mechanistic Studies
10%
Clinical Trials
10%
Low-grade Inflammation
10%
Pharmaceutical Intervention
10%
Cirrhosis
10%
Liver Fibrosis
10%
Autophagy
10%
Hepatocellular Carcinoma
10%
Endoplasmic Reticulum Stress (ER stress)
10%
Disease Pathophysiology
10%
Nonalcoholic Steatohepatitis
10%
Liver Steatosis
10%
Medicine and Dentistry
Diabetes
100%
Nonalcoholic Fatty Liver
100%
Heart Protection
100%
Sodium Glucose Cotransporter
36%
Combination Therapy
18%
Disease
9%
Oxidative Stress
9%
In Vitro
9%
Clinical Trial
9%
Programmed Cell Death
9%
Pathophysiology
9%
Disease Exacerbation
9%
Disease Course
9%
Hepatocellular Carcinoma
9%
Lifestyle Modification
9%
Endoplasmic Reticulum Stress
9%
Liver Fibrosis
9%
Human Study
9%
Fatty Liver
9%
Liver Cirrhosis
9%
Autophagy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Sodium Glucose Cotransporter
36%
Combination Therapy
18%
Disease
9%
Inflammation
9%
Human Study
9%
Pathophysiology
9%
Clinical Trial
9%
Disease Exacerbation
9%
Liver Fibrosis
9%
Liver Cirrhosis
9%
Disease Course
9%
Liver Cell Carcinoma
9%
Fatty Liver
9%